NGM Biopharmaceuticals, Inc.
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 3 name spellings.
0
Ending by 2030
Jun 2032
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 2 fees due Dec 6 to 18, 2026 · next Dec 6
- 1 fee due Jan 28, 2027The maintenance fee for Methods of using compositions comprising variants and fusions of FGF19 polypeptides for reducing glucose levels in a subject (US 9,089,525) comes due Jan 28, 2027. Unpaid by Jul 28, 2027, it lapses early.
- 2 fees due Feb 6 to 22, 2027 · next Feb 6
- 3 fees due Mar 17 to 26, 2027 · next Mar 17
- 4 fees due Apr 8 to 30, 2027 · next Apr 8
- 2 fees due Jun 19 to 30, 2027 · next Jun 19
- 1 fee due Aug 18, 2027The maintenance fee for Compositions and Methods of Use for Treating Metabolic Disorders (US 10,562,965) comes due Aug 18, 2027. Unpaid by Feb 18, 2028, it lapses early.
- 1 fee due Sep 1, 2027The maintenance fee for Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases (US 9,273,107) comes due Sep 1, 2027. Unpaid by Mar 1, 2028, it lapses early.
Recent changes
- 1 term has ended since Aug 23, 2026
- Sep 11 US 10,071,139 Methods for Treatment of Conditions Associated with Elevated Triglycerides with an ANGPTL8 Polypeptide Fragment · lapsed on the fee record
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,951,966 | Compositions Comprising Variants and Fusions of FGF19 Polypeptides, and Uses and Methods Thereof for Treatment of Metabolic Disorders and Diseases In force · High confidence | In force | High confidence | |
| US 9,089,525 | Methods of using compositions comprising variants and fusions of FGF19 polypeptides for reducing glucose levels in a subject In force · USPTO record | In force | USPTO record | |
| US 9,670,260 | Compositions comprising fusion variants of FGF19 polypeptides In force · USPTO record | In force | USPTO record | |
| US 9,751,924 | Methods of using compositions comprising fusion variants of FGF19 polypeptides for reducing glucose levels in a subject In force · USPTO record | In force | USPTO record | |
| US 9,580,483 | Methods of using compositions comprising variants and fusions of FGF19 polypeptides for treatment of diabetes In force · USPTO record | In force | USPTO record | |
| US 11,065,302 | Compositions comprising fusion variants of FGF19 polypeptides In force · USPTO record | In force | USPTO record | |
| US 10,413,590 | Methods of using compositions comprising variants of FGF19 polypeptides for reducing body mass in a subject In force · USPTO record | In force | USPTO record | |
| US 10,195,250 | Compositions and Methods of Use for Treating Metabolic Disorders In force · Low confidence | In force | Low confidence | |
| US 9,273,107 | Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases In force · USPTO record | In force | USPTO record | |
| US 11,564,972 | Methods of Using Compositions Comprising Variants of FGF19 Polypeptides for Treating Primary Biliary Cirrhosis in a Subject In force · Low confidence | In force | Low confidence |
Also on record, not counted in the 44: 29 lapsed for an unpaid fee. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
3 pending · 5 abandoned · 37 no status recorded